 Source: ra2 studioShutterstock Today may be less than stellar for Relmada Therapeutics NASDAQ: RLMD , but its certainly a great day for Axsome Therapeutics NASDAQ: AXSM . Apparently, Relmadas depressive disorder drug candidate failed to achieve its primary clinical trial endpoint. 